​

Bicara Therapeutics Stock (NASDAQ:BCAX)

ForecastOwnershipFinancialsChartTranscripts
Bicara Therapeutics by TradingView

Previous Close

$17.61

52W Range

$13.70 - $30.99

50D Avg

$20.97

200D Avg

$21.33

Market Cap

$1.13B

Avg Vol (3M)

$692.63K

Beta

-0.82

Div Yield

-

BCAX Company Profile

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

103

IPO Date

Sep 13, 2024

Website

BCAX Performance

BCAX Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-82.39M$-39.89M$-37.66M
Net Income$-68.00M$-51.98M$-37.84M
EBITDA$-82.39M$-51.96M$-37.72M
Basic EPS$-0.40$-1.00$-0.73
Diluted EPS$-0.40$-1.00$-0.73

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 26Aug 11, 26 | 8:30 AM
Q1 26May 11, 26 | 8:30 AM
Q4 25Mar 30, 26 | 8:30 AM

Peer Comparison

TickerCompany
CMPXCompass Therapeutics, Inc.
CBIOCrescent Biopharma, Inc.
VRXAVeraxa Biotech Holding AG
MGNXMacroGenics, Inc.
CNTXContext Therapeutics Inc.
CGEMCullinan Therapeutics, Inc.